乳腺癌蒽环类治疗中心肌肌钙蛋白自身抗体与癌症治疗相关心功能障碍
该研究为PRADA试验的二次分析,纳入119例接受表阿霉素治疗的乳腺癌患者,用研究性免疫分析法检测心肌肌钙蛋白自身抗体(cTnAAb)。cTnAAb阳性率为5%(6例),阳性者基线及首周期后高敏肌钙蛋白I浓度略高,但cTnAAb与癌症治疗相关心功能障碍(CTRCD)发生无关联。
要点
- 乳腺癌蒽环类治疗患者中cTnAAb阳性率低(5%)。
- cTnAAb阳性者基线及首周期后高敏cTnI略高。
- 未发现cTnAAb与CTRCD发生相关。
核心结论
- 该乳腺癌队列中cTnAAb阳性率低,且cTnAAb与CTRCD发生无关联。
研究设计与样本
- PRADA试验的二次分析,纳入119例接受5-氟尿嘧啶、表阿霉素和环磷酰胺治疗(联合或不联合曲妥珠单抗和/或放疗)的乳腺癌患者。
- 在基线、第1周期后、表阿霉素治疗完成时、可能额外治疗后及2年随访时采血,用研究性免疫分析法检测cTnAAb。
主要发现
- 6例(5%)检出cTnAAb,其中3例(50%)发生轻度CTRCD;cTnAAb阴性者113例中68例(60%)发生轻度CTRCD(p=1.0)。
- cTnAAb阳性者基线高敏肌钙蛋白I(Abbott)中位数[95%CI]为2.1[1.5,6.1]ng/L,高于阴性者的0.8[0.8,1.2]ng/L(p<0.001)。
- 首周期蒽环类后cTnAAb阳性者为2.3[1.1,7.1]ng/L,高于阴性者的1.2[0.8,1.3]ng/L(p<0.05);蒽环类治疗完成后未见差异。
关键数值与推荐
- cTnAAb阳性率5%(6/119)。
- cTnAAb阳性者轻度CTRCD发生率50%(3/6),阴性者60%(68/113),p=1.0。
临床怎么用
- 接受蒽环类治疗的乳腺癌患者中cTnAAb阳性率低,检测到cTnAAb不提示CTRCD风险增加。
- cTnAAb阳性者基线及首周期后高敏cTnI略高,解读肌钙蛋白结果时需考虑cTnAAb潜在干扰。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cardiac troponins (cTn) are biomarkers for cardiac injury and used for detection and monitoring of cancer therapy-related cardiac dysfunction (CTRCD). However, cTn-specific autoantibodies (cTnAAb) can interfere with cTn measurements. The purpose of this study was to investigate the prevalence of cTnAAbs and whether cTnAAbs associate with the development of CTRCD in breast cancer patients receiving anthracyclines such as epirubicin. METHODS: This study included 119 patients from the PRADA trial, where study drugs metoprolol and candesartan were given concomitantly with 5-fluorouracil, epirubicin and cyclophosphamide therapy with or without trastuzumab and/or radiation. Blood samples obtained at baseline, after 1st cycle and at completion of epirubicin therapy, after possible additional treatment and at 2-year follow-up were analysed for cTnAAbs using an investigational immunoassay. RESULTS: We detected cTnAAbs in 6 patients (5%), out of whom 3 (50%) developed mild CTRCD, whereas 68 out of 113 (60%) cTnAAb-negative patients developed mild CTRCD (p = 1.0). High-sensitivity cTnI (Abbott) concentrations were higher in cTnAAb-positive than negative patients at baseline (median [95% CI] 2.1 [1.5, 6.1] vs. 0.8 [0.8, 1.2] ng/L, p < 0.001) and after the first cycle of anthracyclines (2.3 [1.1, 7.1] vs. 1.2 [0.8, 1.3] ng/L, p < 0.05) but not after completion of anthracycline therapy. CONCLUSIONS: The prevalence of cTnAAbs was low in this breast cancer cohort. The presence of cTnAAbs in circulation was associated with slightly higher initial concentrations of cTnI. No associations between the production of cTnAAbs and the development of CTRCD were observed in this study.
引用
- Junes H, Vinje-Jakobsen V, Heck SL, et al. Cardiac troponin autoantibodies and cancer therapy-related cardiac dysfunction in breast cancer patients receiving anthracycline treatment: secondary analysis of the PRADA study. Clin Chim Acta. 2026. PMID: 42858905. doi:10.1016/j.cca.2026.122893
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。